1 citations
,
December 1997 in “The British Journal of Psychiatry” This document outlines the indications, dosing, side effects, and contraindications for Epilim in epilepsy treatment, with no new research findings presented.
January 2025 in “Dermatology Review” This paper outlines the clinical features of artefactual skin disorder, emphasizing the complexities in diagnosing the self-inflicted lesions that patients deny, and underscores the importance of integrating dermatological, psychiatric, and psychological treatment approaches.
March 2022 in “Research Square (Research Square)” This case report describes a 15-year-old girl with Alopecia Universalis and psychiatric conditions experiencing hair regrowth after self-medicating with cannabis, suggesting it may have therapeutic potential.
March 2021 in “Clin-Alert” This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.
1 citations
,
July 2021 in “Forensic science international” This study found that segmental single hair analysis produced ocfentanil concentration profiles similar to those from hair lock analysis, supporting its use in cases with limited samples.
April 2026 in “Brain Sciences” This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.
November 2023 in “Brain Sciences” This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.
18 citations
,
May 2023 in “Preprints.org” This review provides an overview of caffeine's effects on cancer, cardiovascular, immunological, inflammatory, and neurological diseases, highlighting both its potential benefits, such as neuroprotection and anti-aging, and possible adverse effects like elevated blood pressure, anemia, and migraine.
26 citations
,
January 2018 in “Skin appendage disorders” This review summarizes existing studies on toxic agents that can cause alopecia, with thallium and colchicine having the most established links, while others like botulinum toxin A need further investigation.
August 2025 in “Biomolecules” This review discusses the potential topical benefits of cannabidiol in dermatology and cosmetics, highlighting its diverse effects and therapeutic roles but reports no new clinical results, emphasizing the need for further research.
43 citations
,
July 2023 in “Pharmaceuticals” This review explores the effects of caffeine on cancer, cardiovascular, immunological, inflammatory, and neurological diseases, including its use in sports, and discusses advancements in caffeine delivery through novel nanocarrier-based formulations.
4 citations
,
January 2023 in “Medical Journal of Babylon” This clinical trial found that hemp seed oil may be a promising treatment for localized alopecia areata, with notable hair regrowth observed in some patients after eight weeks of use.
3 citations
,
June 2023 in “Medicina” This study provides a detailed overview of 1,295 clinical trials related to alcohol dependence registered on ClinicalTrials.gov, highlighting that 59.15% of these trials have been completed, primarily as interventional studies, with most located in North America.
1 citations
,
November 2023 in “International journal of molecular sciences” This article highlights that while cannabinoids show potential for treating various skin conditions, current evidence is largely preclinical, with a need for comprehensive clinical trials to confirm these promising effects.
June 2023 in “Journal of Education, Health and Sport” This study reviewed existing evidence and concluded that while CBD is an effective treatment for certain epilepsy syndromes, more research is required to establish its safety and effectiveness for conditions like anxiety and Parkinson’s disease, and clinicians should monitor ongoing trial results.
2 citations
,
March 2022 in “Indian Journal of Psychiatry/Indian journal of psychiatry” This article reviews the psychiatric conditions associated with HIV, highlighting the bidirectional relationship and management challenges but presents no new research findings.
3 citations
,
November 2024 in “Saudi Pharmaceutical Journal” This review highlights significant health risks associated with anabolic-androgenic steroid use in women and reports no new research results, emphasizing the need for further understanding of their effects on female physiology.
2 citations
,
July 2025 in “Forensic Sciences” This review concludes that anabolic–androgenic steroid abuse may lead to significant neurotoxicity, affecting brain structure, neurotransmitter systems, and increasing the risk of mood disorders and cognitive deficits.
1 citations
,
October 2025 in “Frontiers in Cardiovascular Medicine” This review examines AAS-related deaths and finds that anabolic-androgenic steroid abuse may lead to severe cardiac abnormalities, contributing to fatal arrhythmias and sudden cardiac death in young athletes and bodybuilders.
November 2024 in “Psychoneuroendocrinology” This study found that hair steroid analysis effectively detected increased hormone levels from both a single testosterone dose and laboratory-induced stress, revealing individual context factors like relationship status also impact hair hormone concentrations.
9 citations
,
April 2024 in “Metabolites” This study reviews the current research on the metabolomic profile and antimicrobial properties of the Cannabis plant, highlighting its effective antibacterial activity against multidrug-resistant bacteria while noting a lack of studies on its impact on plant and aquatic pathogens, emphasizing potential agricultural benefits.
3 citations
,
December 2022 in “Cells” This review examines the role of cannabinoid compounds in treating various skin conditions and suggests their potential as systemic and topical therapies, but it reports no new experimental results.
2 citations
,
September 2023 in “Cosmetics” This study reviewed existing research on the use of cannabinoids for hair, scalp, and skin conditions, finding moderate evidence for their efficacy in conditions like atopic dermatitis and psoriasis, but noted limited evidence and no standardized guidelines for treatment.
1 citations
,
March 2023 in “Phytochemistry Reviews” This review discusses the potential of CBD for treating skin disorders, the challenges of its topical administration, and current strategies to improve its application, but reports no new clinical findings.
January 2025 in “Molecules” In this review, the authors discuss caffeine's potential mechanisms and benefits as a hair loss treatment, noting its possible effectiveness and safety, though they caution that existing studies often have significant design flaws.
August 2024 in “Cosmetics” This review highlights caffeine's diverse benefits in cosmetics and nutricosmetics, noting its antioxidant properties, ability to treat skin disorders like androgenic alopecia, and potential to enhance sunscreen effectiveness, though penetration into deeper skin layers remains challenging.
May 2024 in “International Journal of Nanomedicine” This review examined the diverse therapeutic potentials of cannabinoids, highlighting their applications in pain, neurological, and cancer treatments, and emphasized the benefits of biodegradable polymers in improving drug delivery; however, further clinical trials are needed to fully explore these potentials.
188 citations
,
December 2020 in “Foods” This review explores the potential health benefits of food bioactive compounds, specifically polyphenols, as preventive agents against non-communicable diseases like cancer and cardiovascular disorders, while also addressing challenges like bioavailability and industrial applications.
45 citations
,
May 2022 in “Biomedicines” This review discusses using human follicular fluid in metabolomic analysis as a diagnostic tool and predictor of success in assisted reproductive technology for PCOS patients, reporting no new results.
2 citations
,
May 2022 in “International Journal of Impotence Research” This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.